Notably, mice receiving a selective SIRT1 inhibitor with butyrate treatment displayed marked colitis, characterized by high Th17 cell levels and Th17-associated cytokine profile, providing evidence that butyrate therapeutic effect is SIRT1-dependent. This evidence concerns the gene SIRT1 and colitis.